Organogenesis said today it closed a $20 million financing facility with Eastward Capital Partners. “Eastward Capital Partners is committed to partnering with technology-forward companies who are leaders in their industry segments. We are excited to partner with Organogenesis to provide the capital to support their growth plans,” Eastward Partner’s Tim O’Loughlin said in a prepared statement. “We […]
Organogenesis Inc.
Silicon Valley Bank puts up $25m credit line for Organogenesis
Organogenesis said today that it entered into a revolving line of credit agreement with Silicon Valley Bank to provide $25 million in new capital to the regenerative medicine company. “The people of Silicon Valley Bank are not only excellent bankers, but what sets them apart is they also understand business,” Organogenesis chief financial officer Tim […]
Organogenesis acquires NuTech Medical
Organogenesis said today that it acquired NuTech Medical for an undisclosed price. The combined company plans to feature a portfolio of wound care products and surgical biologics. Birmingham, Alabama-based NuTech Medical will keep it’s non-biologics product line as a separate company called NuTech Spine. Get the full story at our sister site, Drug Delivery Business News.
Organogenesis launches PuraPly antimicrobial clinical program
Organogenesis said today that it launched its PuraPly Antimicrobial clinical research program, which will evaluate patients treated with PuraPly AM for up to 12 weeks. The 1st studies have started enrolling patients, according to Organogenesis. The Canton, Mass.-based company’s PuraPly AM is a 510(k)-cleared device indicated for the management of acute and chronic wounds. The […]
Apligraf cell therapy changes genomic profile of chronic wound
Organogenesis Inc. said yesterday that its wound-healing cell therapy Apligraf is the 1st of its kind to significantly change the genomic profile of a treated chronic wound. The claim was supported by new research done at the University of Miami and published in the journal Science Translational Medicine. The team applied Apligraf to a chronic venous leg […]
LimFlow taps Rose for CEO | Personnel Moves
LimFlow taps ex-Direct Flow GM Rose as CEO LimFlow said this week that it tapped former Direct Flow Medical VP and GM Daniel Rose as its new chief executive, with former co-founder & CEO Timothy Lenihan transitioning to chief technology officer. LimFlow is developing a device to create percutaneous venous arterialization in the foot to treat end-stage critical limb […]
Organogenesis skins up $30m for expansion
Organogenesis said yesterday that it raised $30 million from existing investors to back its expansion plans. Canton, Mass.-based Organogenesis makes a line of regenerative medicine products designed to heal wounds. The company said it plans to use the proceeds to expand its sales force and commercial operations and to widen the reach of its PuraPly collagen […]
Former Advanced BioHealing exec Clawson pleads guilty in VA fraud case
Former Advanced BioHealing executive Todd Clawson last week pleaded guilty to federal charges that he bribed U.S. Veterans Affairs Dept. doctors to use the company’s DermaGraft biologic wound dressing. Federal prosecutors accused Clawson, who left the company in 2012, of participating in a scheme to bribe VA physicians to use the DermaGraft diabetic foot ulcer treatment with a […]
MiMedx revives Organogenesis beef
MiMedx (NSDQ:MDXG) CEO Pete Petit last week renewed a beef with regenerative medicine rival Organogenesis, accusing that company of being behind a short-seller’s letter advising investors to bet against MiMedx. Early this year, Marietta, Ga.-based MiMedx bailed out of a lawsuit against Canton, Mass.-based Organogenesis alleging “malicious actions” and interference from Organogenesis in the U.S. Veterans Affairs Dept. decision to stop using its […]
Organogenesis touts CE data on artificial skin grafts
Organogenesis yesterday it is releasing results from a comparative effectiveness analysis of its Apligraf and Dermagraf artificial skin grafts showing superior performance compared to its competitors, and released data from a previous study of its graft being used to treat diabetic foot ulcers. The results will be reported at the Symposium on Advanced Wound Care’s […]
Organogenesis lauds Apligraf CE data
Organogenesis said today that a comparative effectiveness analysis of its Apligraf skin substitute has shown improved outcomes over competitor MiMedx‘s (NSDQ:MDXG) Epifix. The study, published this week in Wound Repair & Regeneration, examined healing rates of patients with diabetic foot ulcers treated either with Apligraf or Epifix. Data from the 218-patient, 99-center retrospective study showed a 97% […]